lenalidomid "helm" 2,5 mg kapsler, hårde
helm ag - lenalidomid - kapsler, hårde - 2,5 mg
lenalidomid "helm ag" 2,5 mg kapsler, hårde
helm ag - lenalidomid - kapsler, hårde - 2,5 mg
midolan 2,5 mg kapsler, hårde
helm ag - lenalidomid - kapsler, hårde - 2,5 mg
remix flydende middel
adama northern europe b.v. - uspecificeret - flydende middel - 0 g/l uspecificeret
lumykras
amgen europe bv - sotorasib - carcinom, ikke-småcellet lunge - antineoplastiske midler - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.
ontilyv
bial portela & companhia s.a. - opicapone - parkinsons sygdom - anti-parkinson-lægemidler - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
lytgobi
taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - antineoplastiske midler - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.